New Drug for HIV/AIDSUS Patients Showing Resistance to Current Treatments

by Medindia Content Team on October 14, 2007 at 12:11 PM
New Drug for HIV/AIDSUS Patients Showing Resistance to Current Treatments

Some good news for HIV/AIDS patients who have developed resistance to current treatments.

The US Food and Drug Administration has approved Isentress, developed by Merck & Co, for adults who are already under treatment.

In a statement Merck said more testing was necessary before it was approved for new HIV patients or children.

Isentress belongs to a class of drugs called integrase inhibitors. These drugs work by blocking the integrase enzyme, which helps HIV replicate by inserting its DNA into new cells. Isentress is the first drug in the class to win FDA approval.

Dr. Anthony Fauci, a noted HIV expert and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said the FDA's approval "will be most welcome in the community of physicians taking care of HIV-infected patients."

"Its mechanism of action is particularly important in that it blocks the ability of the virus to integrate itself into the genes of cells," Fauci said. "This property of the virus to integrate is important in establishing the reservoir of virus in the body that has made it extremely difficult to eradicate HIV, even with prolonged treatment."

Two earlier classes of anti-HIV drugs -- protease and reverse transcriptase inhibitors -- also work by blocking different enzymes involved in HIV replication.

Friday's decision by the FDA will give doctors a new tool to help patients who have developed resistance to existing drugs or who are infected with drug-resistant strains of HIV.

Like protease and reverse transcriptase inhibitors, Isentress will also be prescribed for patients in combination with other drugs to maximize the number of ways the virus is being attacked.

The cost of the recommended daily regimen of Isentress -- a 400 mg tablet taken twice a day -- will be comparable to protease inhibitors, with a wholesale price of $27, Merck said.

Source: Medindia
Font : A-A+


Recommended Readings

Latest AIDS/HIV News

Concerning HIV Surge in India Amid AIDS Progress
The 35th World AIDS Day (WAD) marks an opportunity to review strides in HIV prevention, control, and management, acknowledging achievements.
World AIDS Day 2023 Emphasizes Community Leadership's Power to End HIV Crisis
World AIDS Day 2023 focuses on the theme 'Let Communities Lead,' emphasizing the power of the communities most affected by HIV in bringing an end to AIDS.
HIV-Preventive Drug-PrEP's Usage Barriers Among Young Men
Young men involved in sexual activity with other guys are less aware and stigmatized to access PrEP, an HIV prevention drug.
18 of 20 Vietnam Monkeypox Cases Test HIV-Positive
Though monkeypox can affect anyone, CDC research states that approximately 40% of people diagnosed with monkeypox in the US also test positive for HIV.
HIV Vaccine Clinical Trial Initiates in the United States and South Africa
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Drug for HIV/AIDSUS Patients Showing Resistance to Current Treatments Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests